Nexalin Technology (NXL) said Tuesday that the University of California in San Diego Institutional Review Board has approved the use of its Halo Clarity headset in human subjects in clinical trials.
The headsets will be tested in clinical trials to assess their efficacy in treating mild traumatic brain injury and post-traumatic stress disorder, particularly in military personnel, the company said.
The company and its manufacturing partner have begun preparing the initial shipment of 50 headsets to the university, which is conducting the study independently, Nexalin said.
Nexalin said the headset is a non-invasive treatment that can be used at home and allows physicians to monitor patient progress remotely.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.